| Dr Nikita Chevalier, MD | |
|
3 S Greenleaf St Ste J, Gurnee, IL 60031-3377 | |
| (847) 599-1111 | |
| (847) 599-1148 |
| Full Name | Dr Nikita Chevalier |
|---|---|
| Gender | Female |
| Speciality | Urology |
| Experience | 14 Years |
| Location | 3 S Greenleaf St Ste J, Gurnee, Illinois |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1457613531 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | 036.145384 (Illinois) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Advocate Condell Medical Center | Libertyville, IL | Hospital |
| Midwestern Region Med Center | Zion, IL | Hospital |
| Northwestern Lake Forest Hospital | Lake forest, IL | Hospital |
| Vista Medical Center East | Waukegan, IL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Patient First Inc | 3274446596 | 90 |
| Uropartners Llc | 9436182946 | 118 |
News Archive
The study by researchers in the Department of Pharmacology and the CRC for Chronic Inflammatory Diseases found that mice exposed to four days of cigarette smoke displayed significant loss of appetite, fat tissue and body weight.
The New York Blue Light Symposium convened in New York from June 26-27, 2015. The event was sponsored by the International Blue Light Society (Senior Representative: Kazuo Tsubota), which was founded to research and release findings on the effects of blue light on the human body.
A targeted drug shown to improve the outcome of certain breast cancer patients may be of use in the treatment of advanced cases of bladder cancer, according to new research led by the University of Michigan Comprehensive Cancer Center.
AstraZeneca and MedImmune, its global biologics research and development arm, announced today that the US Food and Drug Administration has approved LUMOXITI (moxetumomab pasudotox-tdfk) for the treatment of adult patients with relapsed or refractory hairy cell leukemia who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog.
› Verified 7 days ago
| Entity Name | Northwestern Medical Faculty Foundation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1346235314 PECOS PAC ID: 4587576814 Enrollment ID: O20031105000541 |
News Archive
The study by researchers in the Department of Pharmacology and the CRC for Chronic Inflammatory Diseases found that mice exposed to four days of cigarette smoke displayed significant loss of appetite, fat tissue and body weight.
The New York Blue Light Symposium convened in New York from June 26-27, 2015. The event was sponsored by the International Blue Light Society (Senior Representative: Kazuo Tsubota), which was founded to research and release findings on the effects of blue light on the human body.
A targeted drug shown to improve the outcome of certain breast cancer patients may be of use in the treatment of advanced cases of bladder cancer, according to new research led by the University of Michigan Comprehensive Cancer Center.
AstraZeneca and MedImmune, its global biologics research and development arm, announced today that the US Food and Drug Administration has approved LUMOXITI (moxetumomab pasudotox-tdfk) for the treatment of adult patients with relapsed or refractory hairy cell leukemia who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog.
› Verified 7 days ago
| Entity Name | Patient First Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548258072 PECOS PAC ID: 3274446596 Enrollment ID: O20031111000788 |
News Archive
The study by researchers in the Department of Pharmacology and the CRC for Chronic Inflammatory Diseases found that mice exposed to four days of cigarette smoke displayed significant loss of appetite, fat tissue and body weight.
The New York Blue Light Symposium convened in New York from June 26-27, 2015. The event was sponsored by the International Blue Light Society (Senior Representative: Kazuo Tsubota), which was founded to research and release findings on the effects of blue light on the human body.
A targeted drug shown to improve the outcome of certain breast cancer patients may be of use in the treatment of advanced cases of bladder cancer, according to new research led by the University of Michigan Comprehensive Cancer Center.
AstraZeneca and MedImmune, its global biologics research and development arm, announced today that the US Food and Drug Administration has approved LUMOXITI (moxetumomab pasudotox-tdfk) for the treatment of adult patients with relapsed or refractory hairy cell leukemia who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog.
› Verified 7 days ago
| Entity Name | Uropartners Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073567905 PECOS PAC ID: 9436182946 Enrollment ID: O20050915000277 |
News Archive
The study by researchers in the Department of Pharmacology and the CRC for Chronic Inflammatory Diseases found that mice exposed to four days of cigarette smoke displayed significant loss of appetite, fat tissue and body weight.
The New York Blue Light Symposium convened in New York from June 26-27, 2015. The event was sponsored by the International Blue Light Society (Senior Representative: Kazuo Tsubota), which was founded to research and release findings on the effects of blue light on the human body.
A targeted drug shown to improve the outcome of certain breast cancer patients may be of use in the treatment of advanced cases of bladder cancer, according to new research led by the University of Michigan Comprehensive Cancer Center.
AstraZeneca and MedImmune, its global biologics research and development arm, announced today that the US Food and Drug Administration has approved LUMOXITI (moxetumomab pasudotox-tdfk) for the treatment of adult patients with relapsed or refractory hairy cell leukemia who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog.
› Verified 7 days ago
| Entity Name | Southern Illinois Medical Services Nfp |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770656837 PECOS PAC ID: 3678677390 Enrollment ID: O20070404000595 |
News Archive
The study by researchers in the Department of Pharmacology and the CRC for Chronic Inflammatory Diseases found that mice exposed to four days of cigarette smoke displayed significant loss of appetite, fat tissue and body weight.
The New York Blue Light Symposium convened in New York from June 26-27, 2015. The event was sponsored by the International Blue Light Society (Senior Representative: Kazuo Tsubota), which was founded to research and release findings on the effects of blue light on the human body.
A targeted drug shown to improve the outcome of certain breast cancer patients may be of use in the treatment of advanced cases of bladder cancer, according to new research led by the University of Michigan Comprehensive Cancer Center.
AstraZeneca and MedImmune, its global biologics research and development arm, announced today that the US Food and Drug Administration has approved LUMOXITI (moxetumomab pasudotox-tdfk) for the treatment of adult patients with relapsed or refractory hairy cell leukemia who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Nikita Chevalier, MD 3 S Greenleaf St Ste J, Gurnee, IL 60031-3377 Ph: (847) 599-1111 | Dr Nikita Chevalier, MD 3 S Greenleaf St Ste J, Gurnee, IL 60031-3377 Ph: (847) 599-1111 |
News Archive
The study by researchers in the Department of Pharmacology and the CRC for Chronic Inflammatory Diseases found that mice exposed to four days of cigarette smoke displayed significant loss of appetite, fat tissue and body weight.
The New York Blue Light Symposium convened in New York from June 26-27, 2015. The event was sponsored by the International Blue Light Society (Senior Representative: Kazuo Tsubota), which was founded to research and release findings on the effects of blue light on the human body.
A targeted drug shown to improve the outcome of certain breast cancer patients may be of use in the treatment of advanced cases of bladder cancer, according to new research led by the University of Michigan Comprehensive Cancer Center.
AstraZeneca and MedImmune, its global biologics research and development arm, announced today that the US Food and Drug Administration has approved LUMOXITI (moxetumomab pasudotox-tdfk) for the treatment of adult patients with relapsed or refractory hairy cell leukemia who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog.
› Verified 7 days ago
Robert S Saffrin, M.D Urology Medicare: Accepting Medicare Assignments Practice Location: 3 S Greenleaf St, Suite J, Gurnee, IL 60031 Phone: 847-599-1111 Fax: 847-599-1148 | |
Dr. Harsh Kumar, MD Urology Medicare: Not Enrolled in Medicare Practice Location: 1 S Greenleaf St, # E, Gurnee, IL 60031 Phone: 847-623-4010 Fax: 847-623-4077 | |
Dr. Raza M Khan, M.D Urology Medicare: Accepting Medicare Assignments Practice Location: 3 S Greenleaf St, Suite J, Gurnee, IL 60031 Phone: 847-599-1111 Fax: 847-599-1148 | |
Dr. Nejd F Alsikafi, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 3 S Greenleaf St, Suite J, Gurnee, IL 60031 Phone: 947-599-1111 Fax: 847-599-1148 | |
Sutchin Patel, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 3 S Greenleaf St, Ste. J, Gurnee, IL 60031 Phone: 847-599-1111 Fax: 847-599-1148 | |
Dr. Bruce Allen Brown, M.D. Urology Medicare: Not Enrolled in Medicare Practice Location: 6440 Grand Ave, Suite 206, Gurnee, IL 60031 Phone: 847-782-8349 Fax: 847-782-8546 |